ABT-594, a novel cholinergic channel modulator, is efficacious in nerve ligation and diabetic neuropathy models of neuropathic pain

Brain Research

Volumn 801, Issue 1-2, 1998, Pages 158-163

  Bannon, A W ^a,b   Decker, M W ^a   Kim, D J B ^a   Campbell, J E ^a   Arneric, S P ^a,c  

^a ABBOTT LABORATORIES   (United States)

^b AMGEN INC   (United States)

^c DUPONT COMPANY   (United States)

Author keywords

Allodynia; Chung model; Diabetic neuropathy; Hyperalgesia; Morphine; Nicotinic acetylcholine receptor

Indexed keywords

5 (2 AZETIDINYLMETHOXY) 2 CHLOROPYRIDINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; MORPHINE; UNCLASSIFIED DRUG;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DRUG EFFICACY; HYPERALGESIA; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NERVE LIGATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANALGESICS, NON-NARCOTIC; ANIMALS; AZETIDINES; CHOLINERGIC ANTAGONISTS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERALGESIA; INJECTIONS, INTRAPERITONEAL; LIGATION; LUMBOSACRAL REGION; MALE; MORPHINE; PAIN; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; SPINAL NERVES; TIME FACTORS;

EID: 0032504712     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(98)00596-4     Document Type: Article

References (25)

1. Bannon A.W., Decker M.W., Curzon P., Buckley M.J., Kim D.J.B., Radek R.J., Lynch J.K., Wasicak J.T., Arnold W.H., Holladay M.W., Arneric S.P. ABT-594 [5-((2R)-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors: II In vivo characterization. J. Pharmacol. Exp. Ther. 285:1998;787-794.
2. Bannon A.W., Decker M.W., Holladay M.W., Curzon P., Donnelly-Roberts D., Puttfarcken P.S., Bitner R.S., Diaz A., Dickenson A.H., Porsolt R.D., Williams M., Arneric S.P. Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. Science. 279:1998;77-81.
3. R.S. Bitner, A.L. Nikkel, P. Curzon, S.P. Arneric, A.W. Bannon, M.W. Decker, Role of the nucleus raphe magnus in antinociception produced by ABT-594: immediate early gene responses possibly linked to neuronal nicotinic acetylcholine receptors on serotonergic neurons, J. Neuroscience, 1998, in press.
4. Chaplan S.R., Bach F.W., Pogrel J.W., Chung J.M., Yaksh T.L. Quantitative assessment of tactile allodynia in the rat paw. J. Neurosci. Meth. 53:1994;55-63.
5. Coderre T.J., Katz J., Vaccarino A.L., Melzack R. Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain. 52:1993;259-285.
6. Coderre T.J., Vaccarino A.L., Melzack R. Central nervous system plasticity in the tonic pain response to subcutaneous formalin injection. Brain Res. 535:1990;255-258.
7. Cook A.J., Woolf C.J., Wall P.D., McMahon S.B. Dynamic receptive field plasticity in rat spinal cord dorsal horn following C-primary afferent input. Nature. 325:1987;151-153.
8. Courteix C., Bardin M., Chantelauze C., Lavarenne J., Eschalier A. Study of the sensitivity of the diabetes-induced pain model in rats to a range of analgesics. Pain. 57:1994;153-160.
9. Courteix C., Eschalier A., Lavarenne J. Streptozotocin-induced diabetic rats: Behavioral evidence for a model of chronic pain. Pain. 53:1993;81-88.
10. Decker M.W., Bannon A.W., Buckley M.J., Kim D.J.B., Holladay M.W., Ryther K.B., Lin N.-H., Wasicak J.T., Williams M., Arneric S.P. Antinociceptive effects of the novel neuronal nicotinic acetylcholine receptor agonist, ABT-594, in mice. Eur. J. Pharmacol. 346:1998;23-33.
11. Dixon W.J. Efficient analysis of experimental observations. Ann. Rev. Pharmacol. Toxicol. 20:1980;441-462.
12. Donnelly-Roberts D.L., Puttfarcken P.S., Kuntzweiler T.A., Briggs C.A., Anderson D.J., Campbell J.E., Manelli A., Piatonni-Kaplan M., McKenna D.G., Wasicak J.T., Holladay M.W., Williams M., Arneric S.P. ABT-594 ((R)-5-(2-Azetidinylmethoxy)-2-Chloropyridine): I. In vitro profile of a novel analgesic neuronal acetylcholine (nAChR) ligand. J. Pharmacol. Exp. Ther. 285:1998;777-786.
13. Dray A., Urban L., Dickenson A. Pharmacology of chronic pain. Trends Pharmacol. Sci. 15:1994;190-197.
14. Galer B.S. Neuropathic pain of peripheral origin: advances in pharmacologic treatment. Neurology. 45:1995;s17-s25.
15. Holladay M.W., Wasicak J.T., Lin N.H., He Y., Ryther K.B., Bannon A.W., Buckley M.J., Kim D.J.B., Decker M.W., Anderson D.J., Campbell J.E., Kuntzweiler T.A., Donnelly-Roberts D.L., Piattoni-Kaplan M., Briggs C.A., Williams M., Arneric S.P. Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors. J. Med. Chem. 41:1998;407-412.
16. Jett M.F., McGuirk J., Waligora D., Hunter J.C. The effects of mexiletine, desipramine and fluoxetine in rat models involving central sensitization. Pain. 69:1997;161-169.
17. Kim S.H., Chung J.M. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain. 50:1992;355-363.
18. Kinnman E., Levine J.D. Sensory and sympathetic contributions to nerve injury-induced sensory abnormalities in the rat. Neuroscience. 64:1995;751-767.
19. Lekan H.A., Carlton S.M., Coggeshall R.E. Sprouting of AB fibers into lamina II of the rat dorsal horn in peripheral neuropathy. Neurosci. Lett. 208:1996;147-150.
20. M.B. Max, Antidepressant drugs as treatments for chronic pain: efficacy and mechanisms, in: B. Bromm, J.E. Desmedt (Eds.), Advances in pain research and therapy, Raven Press, New York, 1995, pp. 501-515.
21. Munglani R., Harrison S.M., Smith G.D., Bountra C., Birch P.J., Elliot P.J., Hunt S.P. Neuropeptide changes persist in spinal cord despite resolving hyperalgesia in a rat model of mononeuropathy. Brain Res. 743:1996;102-108.
22. Ollat H., Cesaro P. Pharmacology of neuropathic pain. Clin. Neuropharmacol. 18:1995;391-404.
23. Satoh O., Omote K. Roles of monoaminergic, glycinergic and GABAergic inhibitory systems in the spinal cord in rats with peripheral mononeuropathy. Brain Res. 728:1996;27-36.
24. Simon G.S., Dewey W.L. Narcotics and diabetes: 1. The effects of streptozotocin-induced diabetes on the antinociceptive potency of morphine. J. Pharmacol. Exp. Ther. 218:1981;318-323.
25. Yaksh T.L., Wilson P.R. Spinal serotonin terminal system mediates antinociception. J. Pharmacol. Exp. Ther. 208:1979;446-453.